Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CMDI - 15-12G filed today.
COMPREHENSIVE MEDICAL DIAGNOSTICS GROUP INC
Dormant since 2001
No OS on pinksheets.com
Knobias info:
Authorized Shares: 50,000,000
Source: 10QSB/A ( 06/18/2001 )
Outstanding Shares: 20,668,694
Source: 10QSB/A ( 06/18/2001 )
IMHO I see this as a longer term investment. They have a rework plan for 120, presently they are reworking the second group of 4 wells and shold be done in 2 weeks per their PR. The only thing that may cause a run in the near term is good news from South America or a new deal here is the US. A successfuly recompletion of a second well in Port Arthur can also move it. I'm curious about the South American operation and what kind of PRs we'll be seeing from it. You can make pretty good money being a middle man if you have good contacts. Pinkies are risky but these guys have drilling experience. All IMHO, gotta do your own DD.
Wave, I dont remember having a CFO before. Good news.
I noticed they PDF'd the last 5 PRs on their website, the dates on the PDFs are 3.20.07. IMHO this helps make the PRs more legit as it was done since Rees has taken over. These PRs cover several leases.
Likewise.
SBRX News
Stonebridge Resources Exploration Commences Re-Completion of Kansas Wells
HOUSTON, Mar 28, 2007 (PrimeNewswire via COMTEX) -- Stonebridge Resources Exploration Ltd. (Pink Sheets:SBRX) (Frankfurt:S3C) has begun re-completion of 4 wells located on the Ewing B lease in Kansas. The wells, located in the Squirl and Bartelsville zones, are expected to be completed within two weeks. The Company will report production numbers as soon as they become available.
It is expected the wells should produce 25-30 bbls of oil per day. Stonebridge will continue its strategy to initiate the re-working of 4 wells per month. There are currently 120 producing wells on the Kansas located properties.
About Stonebridge Resources Exploration, Ltd.
Stonebridge Resources Exploration, Ltd. (www.otcsbrx.com) has embarked on a new direction which is primarily engaged in the acquisition, development, exploration and production of crude oil and natural gas. Its focus has shifted to aggressively acquiring working interests in crude oil and natural gas properties. The company intends to use modern development methods along with improved drilling technologies to increase well production by up to 500%. The company's goal is to achieve a high return on its investment by limiting its acquisition costs and by practicing sound and intelligent approaches to oil and gas exploration and development.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other
factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general
economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development
and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any
forward-looking statement to conform the statement to actual results or changes
in the company's expectations.
This news release was distributed by PrimeNewswire, www.primenewswire.com
SOURCE: Stonebridge Resources Exploration Ltd.
By Staff
CONTACT: Stonebridge Resources Exploration Ltd. Investor Relations Steve Christian (281) 894-6300
NEWS!
Stonebridge Resources Exploration Commences Re-Completion of Kansas Wells
HOUSTON, Mar 28, 2007 (PrimeNewswire via COMTEX) -- Stonebridge Resources Exploration Ltd. (Pink Sheets:SBRX) (Frankfurt:S3C) has begun re-completion of 4 wells located on the Ewing B lease in Kansas. The wells, located in the Squirl and Bartelsville zones, are expected to be completed within two weeks. The Company will report production numbers as soon as they become available.
It is expected the wells should produce 25-30 bbls of oil per day. Stonebridge will continue its strategy to initiate the re-working of 4 wells per month. There are currently 120 producing wells on the Kansas located properties.
About Stonebridge Resources Exploration, Ltd.
Stonebridge Resources Exploration, Ltd. (www.otcsbrx.com) has embarked on a new direction which is primarily engaged in the acquisition, development, exploration and production of crude oil and natural gas. Its focus has shifted to aggressively acquiring working interests in crude oil and natural gas properties. The company intends to use modern development methods along with improved drilling technologies to increase well production by up to 500%. The company's goal is to achieve a high return on its investment by limiting its acquisition costs and by practicing sound and intelligent approaches to oil and gas exploration and development.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other
factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general
economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development
and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any
forward-looking statement to conform the statement to actual results or changes
in the company's expectations.
This news release was distributed by PrimeNewswire, www.primenewswire.com
SOURCE: Stonebridge Resources Exploration Ltd.
By Staff
CONTACT: Stonebridge Resources Exploration Ltd. Investor Relations Steve Christian (281) 894-6300
Someone is slowly accumulating WWNG, maybe another pump and dump coming up.
Unusual volume in first half hour. Good news coming?
It's still early but the bid and ask are up there. Looking good.
There was a rumor that Iran attacked US and Brities ships, it wasn't true but OIL peacked to $69.
Nice EOD run here.
275K @.004 went thru.
.0034 X .004
From an article from 9/5/2006 regarding Froptix
"If such a drug could be engineered and delivered early in the course of the disease, it may rescue and preserve the retina from further damage, the researchers believe.
Kaushal and his group are systematically testing each of the 40 to 45 new molecules in animal models. Earlier this year, Kaushal was among a group who formed an opthalmic pharmaceutical company, Froptix, to advance the drug development process.
"Two years ago, we didn't have anything," Kaushal said. "Now we are hoping to be in a position to develop a meaningful clinical trial in early 2007."
http://www.ocusource.com/main.cfm?page=info&topic=pressroom&article=569
2 interesting points from today PR...
Over 35 million patients suffer from dry AMD in the developed world, yet there are currently no available treatment options. In some patients, dry AMD progresses to wet AMD, a leading cause of adult blindness."
"Froptix Corporation has licensed exclusive rights to technology developed at the University of Florida in Gainesville relating to small molecule therapeutics for retinal and macular degeneration. It has lead compounds for the treatment of dry AMD and retinitis pigmentosa and an extensive pipeline of additional small molecule clinical candidates.
I didn't realize that these managers are 'former' managers of Ivax, does anyone know if they left recently? I wonder if they left to manage this company.
"Dr. Jane Hsiao, former vice chairman and chief technical officer of IVAX Corporation and Steven D. Rubin, former senior vice president and general counsel of IVAX Corporation, will serve on Opko's Board of Directors."
$16MM plus $12MM to be funded by the Frost Group.
"The combined company will be re-named Opko Corporation. It will be headquartered in Miami, Florida and intends to apply to have its shares listed on the American Stock Exchange (AMEX)."
MERGER NEWS
March 27, 2007 - 7:01 AM EDT
Acuity Pharmaceuticals and Froptix Corporation Agree to Mergers with Public Shell; New Company to Develop and Market Drugs for Disorders of the Eye - Combined Company to be Re-Named Opko Corporation
MIAMI, March 27 /PRNewswire-FirstCall/ -- Acuity Pharmaceuticals and Froptix Corporation, privately owned pharmaceutical companies developing novel drugs to treat serious diseases of the eye, and eXegenics, Inc. (OTC Bulletin Board: EXEG), a publicly-traded company with no active operations, have executed a merger agreement that will bring the three companies under one corporate umbrella. The combined company will be re-named Opko Corporation. It will be headquartered in Miami, Florida and intends to apply to have its shares listed on the American Stock Exchange (AMEX).
Acuity's product portfolio includes the pioneering gene silencing agent bevasiranib, which has successfully completed Phase II clinical trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME); a novel product for conjunctivitis in Phase I clinical development; and a pipeline of preclinical candidates to treat serious ophthalmic disorders. Froptix has a number of molecules in preclinical development to treat dry age- related macular degeneration (dry AMD) and other ophthalmic diseases. The new company also intends to develop selected diagnostic products that are complementary to its ophthalmic therapies.
Dr. Phillip Frost, former chief executive officer and chairman of IVAX Corporation, will become chairman and chief executive officer of Opko. Dr. Jane Hsiao, former vice chairman and chief technical officer of IVAX Corporation and Steven D. Rubin, former senior vice president and general counsel of IVAX Corporation, will serve on Opko's Board of Directors. Dr. Dale R. Pfost, currently chairman, president and chief executive officer of Acuity Pharmaceuticals, will become president of Opko.
As part of the transaction, The Frost Group, a private equity group headed by Dr. Frost, has agreed to provide Opko with a $12 million line of credit. A portion of this line of credit has already been committed to help fund the transition to the new organization. Proceeds from this line of credit, along with the approximately $16 million of cash held by eXegenics, are expected to be sufficient to fund the company's upcoming Phase III trial of bevasiranib as maintenance therapy for wet AMD in combination with Lucentis(R) and to support continued progress in other programs.
'We believe ophthalmologic disorders offer major opportunities for improved therapies, and we are optimistic that our new company will develop significant products for the maintenance and restoration of vision,' said Dr. Frost. 'To date, bevasiranib has demonstrated the potential to treat wet AMD along with an excellent clinical safety profile, and we intend to pursue advanced clinical trials for its use as part of a treatment regimen in combination with the VEGF antagonist drugs currently prescribed for this condition. Froptix is developing novel technology for the treatment of dry AMD, a more prevalent disorder for which there currently is no effective therapy. The combined product pipelines contain a variety of other promising compounds for other inflammatory, infectious and degenerative diseases of the eye.'
The transaction between the three parties is expected to close today.
About the Merged Companies
Philadelphia-based Acuity Pharmaceuticals is an ophthalmic pharmaceutical company applying proprietary technologies to the treatment and prevention of diseases of the eye. Acuity's lead clinical compound, bevasiranib, an RNA interference-based molecule targeting vascular endothelial growth factor (VEGF), completed a Phase II trial in wet AMD and a pilot Phase II trial in DME. Bevasiranib demonstrated good safety and encouraging signs of biological activity in both studies. Acuity is applying its drug development expertise to a growing pipeline of novel agents for ophthalmic conditions and is also developing proprietary technologies for ocular drug delivery in support of these programs.
Froptix Corporation has licensed exclusive rights to technology developed at the University of Florida in Gainesville relating to small molecule therapeutics for retinal and macular degeneration. It has lead compounds for the treatment of dry AMD and retinitis pigmentosa and an extensive pipeline of additional small molecule clinical candidates. Over 35 million patients suffer from dry AMD in the developed world, yet there are currently no available treatment options. In some patients, dry AMD progresses to wet AMD, a leading cause of adult blindness.
eXegenics, Inc. does not currently have active operations. Previously, it was engaged in the research, creation and development of drugs for the treatment and prevention of cancer and infectious diseases.
This press release contains 'forward-looking statements,' as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),regarding product development efforts and other non-historical facts about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that advanced clinical trials for our lead product candidate, bevasiranib, may not be commenced or completed on a timely basis or at all, that any of our compounds under development, including bevasiranib, may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. We do not undertake any obligation to update forward-looking statements. We intend that all forward- looking statements be subject to the safe-harbor provisions of the PSLRA.
Contacts: Media:
Corporate: GendeLLindheim BioCom Partners
Dr. Dale Pfost Barbara Lindheim
215 966 6180 212 918-4650
SOURCE Acuity Pharmaceuticals; Froptix Corporation; eXegenics, Inc.
Source: PR Newswire (March 27, 2007 - 7:01 AM EDT)
News by QuoteMedia
www.quotemedia.com
.0004? - em
I'm not sure how helpful this is, the maps are useless but it lists the leases.
http://abyss.kgs.ku.edu/pls/abyss/oil.ogop4.OpPage?f_id=1028004935
Stonebridge Resources to Commence Recompletion of Wells On Kansas Acreage
HOUSTON, Mar 23, 2007 (PrimeNewswire via COMTEX) -- Stonebridge Resources Exploration (Pink Sheets:SBRX) (Frankfurt:S3C) will begin re-completion of 4 wells located on the Ewing B lease in Eastern Kansas. The process, expected to begin next week consists of the de-sanding, re-perforating and re-fracing of the Squirl and Bartelsville zones.
Stonebridge anticipates that results should mirror flow rates from existing wells on the acreage producing an expected 25-30 bbls/per day. The Company has 4 wells that have been re-worked and producing on the Kansas acreage to date.
Stonebridge Resources Exploration, Ltd.
Stonebridge Resources Exploration, Ltd., www.otcsbrx.com, has embarked on a new direction which is primarily engaged in the acquisition, development, exploration and production of crude oil and natural gas. Its focus has shifted to aggressively acquiring working interests in crude oil and natural gas properties. The company intends to use modern development methods along with
improved drilling technologies to increase well production by up to 500%. The company's goal is to achieve a high return on its investment by limiting its acquisition costs and by practicing sound and intelligent approaches to oil and gas exploration and development.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other
factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general
economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes
in the company's expectations.
It's a good sign IMO. As long as the OS hasn't skyrocketed and the PRs put out this year are legit we should be OK. I don't really care if they aquire ESP, there's plenty income in the wells and servicing. Without ESP the estimate from the PRs would put potential earnings around 9 or $10MM.
15-12G filed today.
Has anyone here been able to place an order via Scottrade? I won't have clear funds till Monday, but am wondering if it is possible.
Thanks.
I just saw the last 3...
60k @ .008
50k @ .006
1k @ .008
Yes, the lady that called said he would be happy to answer questions when he gets back.
Just recieved a call from WRNW, Rees is out of the country and will be back in the middle of next week. He'll take calls then.
I'm showing 125k volume, last is .0028 on Scottrade.
I think they are needing AFs and Guide 2 for the LOI company also. I worked for a subsidiary of Baker Hughs a while back when they decided to sell a petrochemical plant. It took us over a week with Arthur Anderson and a large group of representatives from both companies just to inventory the plant, and it took AA much longer to sign off on the bottom inventory line. This will take a while with a couple of hundred wells.
They don't say where this will trade tomorrow. I called a broker at Scottrade this afternoon and was surprised to find he never heard of the gray sheets. Has anyone here contacted a broker about trading on the gray sheets yet?
News........
TYLER, Texas, Mar 21, 2007 (PrimeNewswire via COMTEX) -- Biogenerics Limited (Pink Sheets:BIGN) (GR:D9G) announced that the Company has retained legal counsel to guide and direct it in regards to the recent issue of the Ten Day Suspension of Trading by the Securities and Exchange Commission ("SEC").
It is anticipated that the company's stock will become trading again on March 22nd. At this time, the Company is taking all measures to become a fully compliant, fully reporting company under 10SB rules and regulations of the SEC, along with complying with the requirements of Guide 2 of the Industry Guidelines for oil and gas companies. It is a long detailed process expected to take several months to complete.
As announced in previous press releases, the company will take advice from its legal counsel, the changing of the Company's Name, CUSIP number, trading symbol and trading market at this time to become a fully reporting company.
The Company is continuing with its business operations and will inform shareholders of all business activities through regular press releases.
GNEV - REVERSE MERGER: Our Profile List stock General Environmental Corp., /(OTCBB: GNEV 0.15 x 0.04) issued an 8k announcing they signed an Exchange Agreement for the acquisition of all of the shares of Nexphore Technologies, Inc. (Nexphlore"), a Texas corporation in exchange for 50,678,000 post -reverse split common shares. The transaction is expected to close on or before March 31, 2007. Nexplore is engaged in the development of software for use as a search engine.
shellstockreview.com
Global Energy
http://www.globalenergygpcorp.com/
PDVSA website.
"PDVSA considers to reach one production of 5 million 847 thousand daily barrels for year 2012. "
http://www.pdvsa.com/
News!
HOUSTON, March 20, 2007 (PRIME NEWSWIRE) -- Stonebridge Resources Explorations Ltd. (Pink Sheets:SBRX) (GR:S3C) has signed a Memorandum of Understanding to purchase 51% of Global Energy Gas and Power Corporation. Global Energy has approved contacts and service agreements with Petroleos de Venezuela (PDVSA).
PDVSA is the Venezuelan state-owned petroleum company. It has activities in exploration, production, refining and exporting oil, as well as exploration and production of natural gas.
Stonebridge CEO Phillip Christian stated, "This is a huge step forward for the Company given the opportunity to expand our business philosophy and presence into South America. This will undoubtedly be advantageous to Stonebridge, creating new expanding business developments in the area. We look forward to building a continued long term business relationship with Petroleos de Venezuela (PDVSA)."
About Stonebridge Resources Exploration, Ltd.
Stonebridge Resources Exploration, Ltd. (www.otcsbrx.com) has embarked on a new direction which is primarily engaged in the acquisition, development, exploration and production of crude oil and natural gas. Its focus has shifted to aggressively acquiring working interests in crude oil and natural gas properties. The company intends to use modern development methods along with improved drilling technologies to increase well production by up to 500%. The company's goal is to achieve a high return on its investment by limiting its acquisition costs and by practicing sound and intelligent approaches to oil and gas exploration and development.